Abstract. Now more than ever, the management of age-related problems, from cardiovascular morbidity to bone pathology, is increasingly relevant for HIV physicians. Low bone mineral density (BMD) and fractures are more common in HIV-infected patients. Although a multifactorial aetiology underlies this condition, increasing evidence suggests a role for antiretroviral therapy in low BMD, especially upon initiation. This review will detail the epidemiology, pathogenesis, diagnosis and management of osteoporosis and low BMD in HIV-infected patients, with particular emphasis on aging.
Introduction
Between 2001 and 2004, the percentage of all HIV cases in patients older than 50 increased from 17% to 24%; 1 by 2015, it is estimated that almost 50% of those with HIV will be aged over 50 years. 2 Now more than ever, the management of agerelated problems, from cardiovascular morbidity to bone pathology, is increasingly relevant for HIV physicians. As HIV-infected patients age, there is a perception that they are at increased risk of developing common diseases of aging at a younger age. 3 Osteoporosis, osteomalacia and osteonecrosis have all been described in the setting of HIV infection. This review will detail the epidemiology, pathogenesis, diagnosis and management of osteoporosis and low bone mineral density (BMD) in HIV-infected patients, with an emphasis on the older HIV-infected patient.
Osteoporosis is a systemic skeletal disease of low bone mass and disturbed bone microarchitecture. 4 Diagnosis of osteoporosis is based on measurement of BMD, usually by dual energy X-ray absorptiometry (DEXA). BMD accounts for~70% of bone strength and has been shown to correlate inversely with fracture risk. A reduction in BMD of one standard deviation from the norm increases fracture risk two-fold. According to World Health Organization (WHO) definitions (Table 1) , a T-score of less than -1 (one standard deviation below the reference normal value) is termed osteopaenia or low BMD, while a T-score of less than -2.5 is considered osteoporotic. 5 In the USA, more than 10 million patients have osteoporosis, with a further 33.6 million having low BMD. 6 The principal clinical consequence of low BMD and osteoporosis is fracture. Typical fracture sites include the hip, vertebrae and wrist, although fracture rates at other anatomical sites are probably higher in those with osteoporosis. Although low-impact or low-velocity fractures (i.e. those occurring as a result of trauma that would normally not cause a fracture) are more common in those with osteoporosis, it would appear that risk of all fractures, including high-velocity fractures, increases with reduced BMD. 7 Bone mass is determined by peak bone mass, normally attained in the third decade of life, and the subsequent rate of bone resorption (the process whereby mineral is mobilised from bone). In the general population, bone mass increases until the age of 25-35, after which it gradually declines. In females, bone mass is almost completely accrued between the ages of 11 and 14, although continued gains can be made up to the age of 30, while bone mass in males increases markedly during puberty and normally peaks by the mid to late twenties. After peak bone mass is attained, BMD gradually declines, with an abrupt fall in BMD in perimenopausal women associated with falling oestrogen levels. 8 Loss of oestrogen results in increased bone turnover and reduced BMD. The natural history of changes in BMD in men is less clearly defined but reductions in BMD would seem to occur later, and are associated with changes in calcium metabolism and androgen deficiency. While oestrogen deficiency results in relatively rapid bone loss, androgen deficiency leads to a slower rate of decline in BMD. However, oestrogen also plays an important role in men: the Swedish and USA Osteoporotic Fractures in Men cohorts (MrOS) found that men with a lower level of oestrogen had a greater risk of fracture. 9, 10 This increased risk was not seen with low testosterone levels. While the WHO criteria (Table 1) were developed from data on post-menopausal women, some advocate that these guidelines can be applied to men, particularly the elderly.
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In the healthy state, our skeleton is continually remodelled by the coupled processes of bone resorption and bone formation. The purpose of bone remodelling is to repair areas of damaged bone. 12 When this process is uncoupled, the net effect can be reduced bone mass. Although changes in BMD in postmenopausal women and, to a lesser extent, older men have been relatively well defined, in younger people, such as premenopausal women and men below the age of 50, the natural history of changes in BMD are less well understood. In younger individuals, low BMD occurs due to either a failure to achieve peak bone mass, accelerated bone resorption (linked to either hormonal changes or uncoupling of bone remodelling) or a combination of both. Diagnosis of low BMD and osteoporosis in this patient group is complicated as the risk of fracture associated with WHO definitions of osteoporosis are derived from older patient groups and have not been validated in premenopausal women and younger men. In fact, the ability of the T-score to predict fracture in younger people has not been validated and therefore WHO criteria should not be used in isolation to diagnose osteoporosis in this group. An alternative approach is the use of an agematched reference group (Z-score) or a more global assessment of fracture risk (see below). Failure to achieve peak bone mass or rapid loss of BMD can arise due to genetic diseases, chronic illness or medications, with 40-60% of osteoporosis diagnosed in men found to arise secondary to another condition (Table 2) . 13 
Fractures, health implications and economic cost
Fragility fractures are common occurrences; the lifetime incidence of fragility fracture is 50% over the age of 50 in women and 20% in men.
14 Although fracture rates increase with age, the increase in incidence in men lags behind that of women by~10 years. In addition to increasing exponentially with age, the incidence of hip fracture also varies with geographic location with every 10 northward increment in latitude associated with a 0.3% increase in the 10-year risk of hip fracture. 15 In addition to the obvious morbidity associated with fracture, incident fracture increases risk of further fractures, significantly affects quality of life and increases overall mortality, over and above that attributable to the fracture alone. The mortality risk associated with hip fracture persists for 1 year subsequent to fracture and longer than 1 year for vertebral fracture, and would appear to be greater in men. 16 Twenty percent of patients with hip fracture subsequently require long-term care and 40% never regain pre-morbid independence. 17 Hip fractures place a significant economic burden on health services. On the basis of current trends, the number of hip fractures will increase from 46 000 in 1987 to 117 000 in 2016 18 with associated hospital and social care cost in the UK estimated to increase from £1.73 billion to £2.1 billion by 2020.
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HIV infection and bone disease
Studies spanning the past decade have variably reported prevalence of low BMD at between 32% and 71% in HIVinfected populations. [20] [21] [22] [23] [24] [25] [26] [27] Traditional risk factors, HIV-related factors and antiretroviral therapy (ART) have all been implicated in the increased risk of reduced BMD (Table 3) . Certain traditional risk factors are likely to be over-represented in HIV-infected cohorts with smoking rates, lack of physical activity, illicit drug use and low body mass index (BMI) all being commonly reported. Many studies reporting an increased prevalence of low BMD associated with low bodyweight derive from the pre-ART era, while more contemporary studies report a relatively high prevalence of low BMD even in populations with normal BMI. HIV-related factors reported to be associated with reduced BMD include HIV infection, 26,28-30 duration of infection or time since diagnosis, 26, 30, 31 nadir CD4+ T-cell count 27 and HIV RNA. 32 Chronic inflammation and elevated cytokine levels (tumour necrosis factor, interleukin-6) have also been implicated. 33, 34 The role of antiretroviral agents has been controversial. Two meta-analyses have tried to combine the results of the many cross-sectional studies published. However, both had different approaches. The first attempted to address the issue of ART and low BMD. Although those with HIV infection had 6.4 times increased odds of developing low BMD and 3.7-fold increased odds of developing osteoporosis, an analysis restricted to HIVinfected subjects determined that ART was associated with a 2.4-fold increased odds of low BMD compared with ART-naïve patients. 35 The second meta-analysis explored the contribution of low BMI or bodyweight to low BMD, and concluded that much of the association between HIV infection and low BMD was explained by HIV-infected subjects having lower bodyweight rather than an effect of HIV itself. 36 While both meta-analyses appear to provide contrasting results, both were designed to answer different research questions limiting the ability to draw comparisons between the analyses.
Changes in BMD with ART initiation in HIV-infected adults
More recently, greater insights into the natural history of changes in BMD have been derived from prospective, randomised studies. To date, all studies that have examined changes in BMD with ART initiation have demonstrated a consistent and significant decline in BMD during the first year after ART initiation. 22, [37] [38] [39] [40] [41] Treatment initiation with nucleoside analogue reverse transcriptase inhibitors (NRTI) versus NRTI-sparing ART results in greater declines in BMD. Greater reductions have been observed with initiation of ART containing protease inhibitors (PI), NRTI or both. 38, 39 The
ASsessment of Safety and Efficacy with AbacaviR or Tenofovir (ASSERT) study randomised ART-naïve, HIV-infected patients to receive either abacavir-lamivudine or tenofovir-emtricitabine with efavirenz. 39 Significant reductions in BMD at the hip and lumbar spine were demonstrated in both treatment groups; however, BMD loss was greater in the tenofovir group. In contrast, patients on stable ART who were switched to regimens including tenofovir or abacavir experienced further reductions with tenofovir, versus stabilisation or increased BMD with abacavir. 41 The AIDS Clinical Trial Group 5224 study, a randomised four-arm clinical trial, compared ART containing the NRTI tenofovir or abacavir combined with either the nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz or the PI atazanavir. 40 Greater declines in BMD at both the hip and lumbar spine were observed in those randomised to tenofovir versus abacavir, and greater decreases in those randomised to atazanavir versus efavirenz. However, with atazanavir, differences were only observed at the spine. This peculiar observation of significantly greater BMD loss limited to the spine was observed with initiation of PI-based ART in another study.
BMD in HIV-infected youth and elderly people
Fourteen percent of all new HIV infections diagnosed in Europe in 2007 were in those aged 15-25 years. 42 It is expected that younger HIV-infected patients will be at particular risk of bone pathology due to their longer potential exposure to both HIV and ART, and the associated consequences on the ability of these patients to attain peak bone mass. In addition, increased cytokine production arising from HIV infection, growth hormone deficiency and ART all impact this vulnerable age group and may also affect peak bone mass. One study addressed BMD change in children starting tenofovir. The children had significantly reduced Z-scores at baseline, experienced a significant reduction on tenofovir that stabilised after 48 weeks, while BMD increased in those who discontinued tenofovir. 43 While DEXA may underestimate BMD in children due to their small size, it is nonetheless concerning that they may be at even greater risk of BMD loss as they age compared with those acquiring HIV in adulthood.
The majority of studies addressing BMD changes in HIVinfected subjects focus on subjects younger than 50 years of age, and studies involving postmenopausal women and the elderly are relatively few. In a direct comparison of aging cohorts of HIV-infected subjects and the National Health and Nutrition Examination Survey (NHANES) cohort, BMD was similar at the spine but significantly lower at the hip in those with HIV. 44 This is similar to findings in a cross-sectional study of HIV-infected and uninfected individuals over 55, the majority of whom were male and African American. T-scores were significantly reduced at the hip in those with HIV after adjusting for age, race and BMI. In a longitudinal study comparing HIV-infected and uninfected men over the age of 50, less than half of all subjects had normal BMD. 45 However, the risk of developing osteopaenia was far greater in men with HIV infection compared with those without HIV (7.2 per 100 person-years at risk (PYAR) v. 2.6 per PYAR). Of note, the independent associations between heroin use, AIDS and hepatitis C co-infection and reductions in femoral neck BMD underscore both the multifactorial aetiology of BMD loss and the fact that subgroups of HIV-infected patients may be particularly vulnerable to accelerated loss of BMD. A prospective cohort study of a relatively small group of postmenopausal women with and without HIV found significantly lower BMD at the lumbar spine in those with HIV infection after adjustment for age, ethnicity and BMI. HIV infection was associated with elevations in markers of bone resorption and independently associated with lower BMD at the lumbar spine and total hip (P = 0.02 and 0.04 respectively). 46 However, previous data from a similar population demonstrated that BMD at the lumbar spine and hip did not correlate with any HIV or ART variable, and that lowest historical weight and years since menopause were independently associated with lumbar spine and hip BMD. 47 However, the relatively small sample size in both studies may have limited the statistical power to determine less strong associations.
Osteopaenia and osteoporosis: clinical consequences
As previously mentioned, the clinical consequence of low BMD and reduced bone strength is fracture. Whereas many crosssectional and longitudinal studies have reported an increased prevalence of low BMD in HIV-infected patients, until recently, data on fracture prevalence have been lacking. However, in a large epidemiological study reporting fracture rates based on a clinical data registry, the overall fracture prevalence was 2.87 persons with fractures per 100 persons in those with HIV compared with 1.77 in those without HIV. 48 This was observed in both genders, 2.49 per 100 persons v. 1.72 per 100 persons for HIV-positive versus HIV-negative women and 3.08 v. 1.83 fractures per 100 persons for HIV-positive versus HIV-negative men. The greatest differences in fracture prevalence occurred in men over the age of 40 and women over the age of 60. In a comparison of the HIV Outpatient Study cohort to the National Hospital Ambulatory Medical Care Survey (NHAMCS-OPD) cohort, fractures and the relative proportionality of fragility fractures were greater in the HIVinfected subjects. 49 Increasing age, lower nadir CD4 + T-cell counts, hepatitis C co-infection, diabetes mellitus and substance abuse were all independently associated with fractures. A much smaller French cohort estimated fracture risk to be comparable to that of the general population. The authors emphasised that within their cohort, subjects with a history of alcohol abuse or hepatitis C infection had greater risk of fracture, although this study lacked a control group. 50 One study has been published with data pertaining to fractures in elderly cohorts specifically. The Veteran Aging Cohort Study-Virtual Cohort (VACS-VC) demonstrated that fracture risk was elevated in the setting of HIV infection after adjustment for demographics, alcohol use and smoking (adjusted hazard ratio (aHR) 1.24). 51 However, a further adjustment for BMI further reduced the effect of HIV (aHR 1.10).
Ultimately, these data underline the important role that comorbidities, BMI and socioeconomic factors play in the development of bone fragility and fracture. A definitive link between low BMD and fracture, particularly in younger HIVinfected patients, has not been demonstrated. Large longitudinal studies reporting BMD data along with data on trauma, falls risk and fracture are required to clarify the relative importance of BMD, comorbidities and risk behaviour in the development of fractures in patients with HIV infection.
Screening and diagnosis of low BMD
A comprehensive approach to assessing the risk of low BMD and fractures includes detailed history-taking and clinical examination followed by careful consideration of potential secondary causes of osteoporosis (Table 2 ) and appropriate laboratory investigations (Table 4) 13 followed by fracture risk assessment and, if appropriate, DEXA scanning. Decisions regarding treatment are usually directed by national or regional guidelines based on risk assessment and BMD quantification by DEXA.
Data from large international cohorts assessing fracture risk have been developed into risk algorithms that integrate risk factors for fractures, such as age and corticosteroid exposure, with DEXA to better predict overall fracture risk. In 2008, the FRAX ® fracture risk assessment was introduced: an on-line risk assessment tool that utilises regional fracture data and consideration of traditional risk factors to provide a 10-year fracture risk estimate. 52 In addition to providing individualised risk assessments based on country-specific fracture rates, the FRAX score can also be used to calculate thresholds for costeffective pharmacological intervention. Guidelines have been established for treatment on a regional basis, with a 3% risk of hip fracture or a 20% risk of any fragility fracture meeting the treatment threshold in the USA, and the treatment threshold varying with the age of the patient in Europe. The FRAX ® risk calculator, however, has limitations that reduce its utility in an HIV-infected population. As it is only validated in those over 40 years old and does not currently list HIV infection as a secondary cause of osteoporosis, it may arguably underestimate fracture risk in HIV. 53 However, as it can calculate risk without requiring DEXA, it may be useful in identifying those patients at risk for fracture without screening with a DEXA scan, benefiting those clinicians working where access to DEXA is limited. The European AIDS Clinical Society publishes guidelines for the diagnosis and management of bone disease in HIVinfected patients, and currently advises screening for fracture risk every 2 years. Assessment with a DEXA scan is advised for all postmenopausal women, men over the age of 50, those with a history of significant steroid exposure or hypogonadism, or those with a history of fragility fracture. 54 Recent recommendations from the USA, 55 although similar ( Table 5 ), proposed that HIV should be thought of as an additional risk factor in fracture risk assessment. Under these recommendations, potentially more HIV-infected patients may meet the criteria for screening for low BMD with DEXA. Whether either approach is cost effective remains to be determined.
Frailty and falls
Fragility fractures occur in the setting of low BMD and excessive bone mechanical loading (Fig. 1) resulting from a fall or trauma. The frailty phenotype, characterised by weight loss, low physical activity, exhaustion, weak grip and slower walking, has been reported at an earlier age in HIV-infected subjects and in patients with and without ART. 56, 57 Nine percent of patients in one cohort and 12% of postmenopausal women in the Women's Interagency HIV Study (WIHS) were found to have the frailty phenotype. 58, 59 Frailty represents another variable in the multifactorial pathway to fracture risk, and patients with a history of opportunistic infection 58 and a low CD4 + T-cell count may be particularly vulnerable but readily identifiable within a patient cohort.
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Management of low BMD in HIV
Fall risk reduction
Assessment of the risk of falling is important for fracture reduction and should be performed on a case-by-case basis. A Cochrane review of intervention for the prevention of falls found that exercise targeting strength, balance, flexibility and endurance reduced the rates of falls, vitamin D supplementation reduced falls only in the setting of deficiency, and home safety interventions were effective for those at especially a high risk of falling (e.g. visually impaired). 60 Cataract surgery and insertion of pacemakers in those with appropriate indications also reduced the rate of falls.
Vitamin D
Vitamin D, a fat-soluble steroid hormone, is thought to play an important role in conditions as diverse as bone demineralisation, impaired immune function, cardiovascular mortality and the metabolic syndrome. Vitamin D can either be ingested or produced in the skin, where exposure to ultraviolet light produces a photolytic reaction and thermal isomerisation, resulting in production of vitamin D 3 . Subsequent hydroxylation in the liver and kidney creates the active metabolite 1,25(OH) vitamin D 3 . 61 Over the past decade, vitamin D insufficiency and deficiency have been increasingly recognised in the general population. Risk factors such as increasing age, pigmented skin, low sunlight exposure, obesity and insufficient vitamin D intake are associated with reduced vitamin D status. Similarly, vitamin D insufficiency and deficiency are also commonly observed in HIV-infected populations, with less than 10% achieving Mechanical stress Fig. 1 . Multifactorial pathway to fracture. Joint geometry refers to the spatial distribution of bone mass. Structural parameters of the joint crosssectional area, femoral neck shaft angle and hip axis length can be utilised along with age, height and weight to calculate the femoral strength index (the ability of the hip to withstand a fall on the greater trochanter). ART, antiretroviral therapy. 83 optimal levels in one study 62 and severe deficiency (<25 nmol L -1 ) seen in more than one-third of subjects. Several potential factors may explain the low vitamin D status in HIV-infected patients: first, chronic infection with HIV increases tumour necrosis factor-a, which negatively correlates with vitamin D concentrations; 63 and also specific antiretrovirals, such as the NNRTI efavirenz, are likely to accelerate the metabolism of vitamin D. 62 In the Reaching for Excellence in Adolescent Health Cohort (REACH) study, a case-control study of disadvantaged youth with and without HIV, vitamin D levels were found to be similarly low in both HIV-negative and HIV-positive subjects. 64 More data, with appropriately matched HIVnegative control subjects, is required to establish if vitamin D levels are lower with HIV infection or if HIV-infected patients have low vitamin D secondary to additional socioeconomic factors.
While there is debate about the thresholds reported for adequate serum levels of vitamin D, a recent International Osteoporosis Foundation consensus statement suggests that levels above 75 nmol L -1 are advisable to reduce the risk of hip fracture in the general population. 65 To achieve maintenance of optimal vitamin D status, a recommended intake of 800-1000 IU per day is advised, with replacement with vitamin D 3 preferred. The Institute of Medicine recommend dietary reference intake of 400 IU of vitamin D per day for young adults, increasing to 800 IU per day for the elderly. 66 In at least one study, use of vitamin D 3 resulted in attainment of higher overall vitamin D levels. 67 Where a patient is vitamin D deficient and repletion is required, several replacement regimens have been proposed, including replacing 800-2000 IU per day, or replenishing stores with a total of 500 000-10 000 000 IU vitamin D 2 or D 3 over 4-5 weeks in divided doses followed by a period of 4 weeks for level equilibration, after which the 1,25(OH) vitamin D level is checked (Fig. 2) . 68 Once an optimal level is achieved, a maintenance dose of 50 000 IU once monthly is suggested. Failure to achieve optimal levels, even after a second schedule of treatment, should lead to investigation for fat malabsorption. 68 The recent Endocrine Society Clinical Practice Guidelines for evaluation, treatment and prevention of vitamin D deficiency have clarified recommended daily intakes, replacement and maintenance schedules. 69 
Bisphosphonates
Bisphosphonates are first-line agents for the treatment of osteoporosis and have been shown to reduce vertebral and hip fracture incidence in the general population. [70] [71] [72] Studies in HIV-infected patients to date have had heterogenous results, most likely due to methodological differences and small sample size. Once-weekly oral alendronate has been assessed in four studies. [73] [74] [75] [76] The earliest of these selected patients with T-scores of less than -1 and compared their alendronate plus vitamin D (500 IU) and calcium carbonate (1000 mg) to vitamin D and calcium carbonate alone and found no significant difference in change in BMD (femoral neck or lumbar spine) between treatment groups at 52 weeks. 73 Another study similarly compared vitamin D (200 IU) and calcium carbonate (500 mg) with and without oral alendronate in patients with T-scores less than -1.5 but found a significant mean percentage change between treatment arms for lumbar spine (2.29%), hip (2.64%) and trochanter (3.8%) but not for femoral head. 76 The longest treatment study followed osteoporotic patients (T-score less than -2.5) for 96 weeks and observed significant increases in T-scores for the lumbar spine and femoral neck in those on treatment by Week 48. By Week 96, there were significant between-group differences in T-score at the lumbar spine, hip, trochanter and total femoral head. Only dietary advice was given to optimise calcium and vitamin D intake. 75 Data on the use of annual intravenous bisphosphonate (zolendronate) has made it an attractive therapeutic option for patients and physicians. In HIV-infected patients, use of zolendronate resulted in significant increases in BMD at the lumbar spine (+8.9%), total hip (+3.8%) compared with the control group (all P = <0.001). 77 In general, both oral and intravenous bisphosphonate were well tolerated and concerns regarding oversuppression of resorption (potentially leading to reduced fracture healing) have been allayed, to a degree, by the stabilisation of bone biomarkers early in the treatment period after an initial prompt decline. 77 Although these data are reassuring that bisphosphonate treatment can be expected to increase BMD in HIV-infected patients, whether this translates into reduced fracture prevalence remains to be determined, particularly in younger patients. In addition, it has been suggested that prophylactic use of bisphosphonates at ART initiation might abrogate the reduction in BMD seen early in treatment. Studies specifically designed and adequately powered to address these issues are required.
Hormone therapy
Relatively few studies have examined the effect of hormone treatment or replacement on BMD. In one study, intramuscular administration of testosterone in male patients with AIDS wasting syndrome resulted in a significant increase in lumbar spine BMD. 78 Androgen replacement in female subjects has also been shown to significantly increase BMD at the hip and trochanter but not the lumbar spine. 79 Of note, patients did not receive vitamin D or calcium supplementation.
Alternative agents such as strontium ranelate, calcitonin, parathyroid hormone (teriparatide), hormone replacement therapy, raloxifene, osteoprotegrin and the anti-receptor activator of nuclear factor kappa-ß ligand (RANK-L) human 69 Obese subjects and those on medications affecting vitamin D metabolism need higher doses. monoclonal antibody denosumab are yet to be studied in detail in the setting of HIV-infected patients. The latter may be of particular interest in HIV-infected patients as RANK-L has been shown to be increased in ART-treated patients. 80 Finally, there is no evidence that switching patients away from regimens including tenofovir or PI results in beneficial effects on either BMD or fracture risk. When addressing low BMD in HIV, the primary consideration should be to maintain antiretroviral efficacy in patients on stable ART, while taking steps to reduce the risk of falls and assessing the need for pharmacological intervention.
Summary
Low BMD and fractures appear to occur at an increased rate in HIV-infected patients. The increasing prevalence of patients over the age of 50 coupled with a relatively high rate of new infections in late adolescence make these groups particularly vulnerable to the clinical consequence of low BMD. Data correlating low BMD and fracture rate, as well as the economic and social burden of fractures in this population, are required. Bisphosphonates are effective at increasing BMD in this patient population and should be considered in patients at increased fracture risk with low BMD. 
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